Prashant Vempati
Radiation Oncology · New York, NYNPI 1487017935
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Telix Pharmaceuticals at 44.7% of the total. Reporting peaked in 2023 at $352 and has fallen 58.1% since, to $147 in 2025.
Across 11 payments — averaging $59.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Telix Pharmaceuticals$294
- Monteris Medical Corporation$159
- GT Medical Technologies, Inc$143
- Jazz Pharmaceuticals Inc.$26
- AstraZeneca$20
- Novocure Inc.$15
Across 5 payments — averaging $10,209 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$51K
What the payments were for
- Food & beverage$658100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Telix Pharmaceuticals | 3 | $294 |
| Monteris Medical Corporation | 2 | $159 |
| GT Medical Technologies, Inc | 3 | $143 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| AstraZeneca | 1 | $20 |
| Novocure Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUCCIX$224
- Neuroblate$129
How this compares
$658 in reported general payments places this provider in the 60th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 22 | $338 |
| Pantoprazole Sodium | 15 | $57 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in New York
- Michael ZelefskyNew York$946K
- Nancy LeeNew York$233K
- Robert SamsteinNew York$125K
- Jalal AhmedNew York$100K
- Charles SimoneNew York$84K
- Silvia FormentiNew York$57K
- Brandon ImberNew York$44K
- Himanshu NagarNew York$43K
- Chiaojung TsaiNew York$38K
- Christopher BarkerNew York$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.